ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
ADC Therapeutics is eligible to receive up to $435 million, including $55 million upfront, $50 million on first European Commission approval and up to approximately $330 million in additional regulatory and sales milestones ADC Therapeutics to receive royalties from mid-teens up to the mid-twenty percent of net sales in Sobi’s territories Sobi to cost-share in … [Read more…]